Home Daily Intelligence Tracker
    • Plans Blog Contact
    Nephros Inc logo
    NEPH

    Nephros Inc

    MaveScore 23 Low model confidence
    Last Price US$3.49 As of Jul 10, 2026
    DCF Fair Price US$6.19 Research estimate · Jul 10, 2026 +81.2% vs price
    Market Cap US$37.8m Company size context
    7D Performance 2.65% Past 7 days
    1Y Performance -6.18% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 23 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    10/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    6/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    2/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    5/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Nephros Inc Overview

    Industry: Medical Instruments & Supplies

    Sector: Healthcare

    Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the remova Read More

    Nephros Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Nephros Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $5.2M (+6% YoY). Operating income was $0.1M (-83% YoY). Net income was $0.1M (-79% YoY).

    Revenue $5.2M +6% YoY
    Operating income $0.1M -83% YoY
    Net income $0.1M -79% YoY
    Adjusted EBITDA $0.2M reported

    What changed

    • Revenue +6% YoY to $5.2M.
    • Operating income -83% YoY to $0.1M.
    • Net income -79% YoY to $0.1M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 07, 2026 SEC filing 8-K May 07, 2026 SEC filing 10-K/A Apr 30, 2026 SEC filing 10-K Mar 12, 2026 SEC filing 10-Q Nov 06, 2025 SEC filing 8-K Aug 11, 2025 Earnings release Earnings release Aug 11, 2025 SEC filing 10-Q Aug 07, 2025 SEC filing 10-Q May 15, 2025

    Recent News



    Real time breakdown of NEPH stock performance - July 2025 Spike Watch & High Return Trade Opportunity Guides
    9 hours ago
    12 Industrials Stocks Moving In Monday's Intraday Session
    4 hours ago
    Nephros (NEPH) Price Target Increased by 27.27% to 7.14
    22 hours ago

    Earnings Per Share

    Score 3.00/5
    Nephros Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Return on Equity

    Score 1.36/5
    Nephros Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Nephros Inc NEPH US$37.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.92/5
    Nephros Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Nephros Inc NEPH US$37.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Leverage

    Score 3.16/5
    Nephros Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Nephros Inc NEPH US$37.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Nephros Inc logo

    Nephros Inc

    US$3.49

    US$6.19

    +81.2% vs price

    US$37.8m

    2.65%

    -6.18%